| Autor: |
Sun T; Department of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding 071000, China., Sun QL; Department of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding 071000, China., Liu Y; Department of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding 071000, China., Zhang YY; Department of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding 071000, China., Sheng P; Department of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding 071000, China., Cui N; Department of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding 071000, China., Zhang N; Department of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding 071000, China., Wang SH; Department of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding 071000, China., Su D; Department of Critical Care Medicine, Affiliated Hospital of Hebei University, Baoding 071000, China. sudansd069@126.com. |
| Abstrakt: |
In patients with severe septic cardiomyopathy, levosimendan has been found to improve myocardial contractility more effectively than dobutamine, although the underlying mechanisms remain unclear. This study aims to compare the effects of levosimendan and dobutamine on cardiac function and inflammatory markers in patients with septic cardiomyopathy, and to further investigate the advantages and disadvantages of both treatments. We included 40 patients with septic cardiomyopathy treated in the intensive care unit of our hospital from September 2020 to September 2023. The patients were randomly divided into a levosimendan group (n=20) and a dobutamine group (n=20). Plasma concentrations of interleukin-6 (IL-6), interleukin-1beta (IL-1β), and tumor necrosis factor-alpha (TNF-α) were measured by immunofluorescence at the start of treatment, 24 hours, and 48 hours. Cardiac troponin I (cTnI) concentrations were determined by chemiluminescence, and left ventricular ejection fraction (LVEF) was measured using the Simpson method. After 24 hours of treatment, there were no significant differences in IL-6, IL-1β, and TNFα levels between the two groups (P>0.05). However, at 48 hours, the IL-6 level in the levosimendan group was significantly lower than that in the dobutamine group (319.43±226.05 pg/ml vs. 504.57±315.20 pg/ml, P=0.039), while IL-1β and TNF-α levels showed no significant differences (P>0.05). Additionally, the cTnI level in the levosimendan group was significantly lower than that in the dobutamine group (1.01±0.54 ng/ml vs. 1.40±0.63 ng/ml, P=0.042), and LVEF was significantly higher in the levosimendan group (50.60±6.11% vs. 46.90±4.95%, P=0.042). These findings suggest that levosimendan may reduce plasma IL-6 levels, alleviate myocardial injury, and improve myocardial contractility in patients with septic cardiomyopathy compared to dobutamine. |
